Immunicum doses the first patient in a new clinical phase I/II-study in primary liver cancer
The first patient in Immunicum’s clinical phase I/II-study in primary liver cancer today received the initial dose of the therapeutic cancer vaccine INTUVAX®. The Company is also finalizing a clinical phase I/II-study in metastatic renal cell carcinoma, initiated in February 2012 and thus far showing promising data.
The liver cancer study will include a total of 12 patients and is conducted at Sahlgrenska University Hospital in Gothenburg, Sweden. The primary objective is to investigate whether INTUVAX® is safe, but immunological response and overall survival will also be evaluated.
Deprecated: Theme without comments.php is deprecated since version 3.0.0 with no alternative available. Please include a comments.php template in your theme. in /home/i/immunicu/www/wp-includes/functions.php on line 4913